New Delhi: Dengue claimed the life of nine-year-old Nistha Taneja, a resident of Malviya Nagar on Saturday. Her family members alleged she was refused admission by two private hospitals despite the government directions. She succumbed to death at Fortis Hospital in Vasant Kunj.
The unofficial death toll due to dengue touched 29 though the official death toll still stands at 17 as of September 24. Almost 1,700 more dengue cases have been reported in the capital in the last one week, taking the total number of people affected by the disease to 5,471.
Roorkee, October 9, 2017 : Dengue and Chikungunya are known to strike fear in the country every year, so much so that the health graph of the city registers a steep rise in these cases. Both of the water-borne diseases, characterized by high fever and pain in the joints, take a toll on our lives. So far, there is no vaccine to immunize people against the spread of the Dengue and Chikungunya virus. However, researchers at IIT-Roorkee have now discovered that a commonly-utilized de-worming drug can be efficiently used for treatments against Chikungunya.
According to a report by PTI, Shailly Tomar, lead researcher and a professor at Indian Institute of Technology (IIT) Roorkee in Uttarakhand was quoted as saying, “Our research has shown that piperazine, a drug existing in the market, is successful in curbing the spread and replication of the Chikungunya virus in a lab setting.”
The drug, Piperazine, is usually used in de-worming treatments against round-words and pinworms. Using their expertise in virology and structure biology, experts have now discovered the anti-viral capabilities of the drug that can potentially prompt new therapies against the fatal, mosquito borne disease.
The researchers are currently testing the molecule on animals, and will consequently take it to clinical trials.
The molecular details uncovered in the study, which has been published in the journal Antiviral Research, will be additionally used to plan piperazine-derivative medications that are more compelling to fight against the Chikungunya virus.
Using X-ray crystallographic technique, in combination with computational science and fluorescence strategies, the researchers discovered that piperazine binds itself with the hydrophobic (water-hating) pocket of capsid protein present in the Chikungunya virus, which can reduce the spread of the virus.
“This pocket is key to the replication of the virus and its spread inside a host. Inhibiting the pocket prevents budding and spread of the virus and can help in treating the virus effectively using existing drugs,” Tomar said.
Chikungunya has become a major public health concern, with an increasing number of people being plagued by the disease every year.
At present, there are no immunizations or anti-viral medications available to cure Chikungunya, and the treatment is focused on mitigating the side effects related with the disease.
Developing a new anti-viral drug molecule can take up to 10 years. To tend to the disease on an immediate basis, Professor Tomar added, “We are looking at repositioning existing, approved drugs and testing these to see if they might inhibit or kill pathogenic viruses.”
NEW DELHI, Sept 16, 2016: The central government has agreed to reserve 10 percent of the beds in its hospitals for treatment of dengue and chikungunya patients, according to Delhi Health Minister Satyendar Jain.
Jain’s remarks came after meeting Union Health Minister J.P. Nadda at his office here on Friday.
“We had requested Mr Nadda to reserve at least 10 percent beds (1,000 beds) in the central government-run hospitals, like All India Institute of Medical Sciences (AIIMS), Safdarjung Hospital, Ram Manohar Lohia Hospital, etc., for treatment of dengue and chikungunya cases, to which he (Nadda) agreed,” Jain told reporters after the meeting.
Earlier, Jain had sought an appointment with Nadda and also written him a letter requesting the Union Minister to convene a meeting of the health ministers of neighbouring states.